Hyperforin: To be or not to be an activator of TRPC(6)

Reviews of Physiology, Biochemistry and Pharmacology

Volumn 169, Issue , 2015, Pages 1-24

  Friedland, Kristina ^a   Harteneck, Christian ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Calcium homeostasis; Depression; Hyperforin; Ion channel; Protonophore; St. John s wort; TRP channel

Indexed keywords

ACETYLCHOLINE; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); AMYLOID PRECURSOR PROTEIN; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; ARISTOFORIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOCHROME P450; DOPAMINE; GLUTAMIC ACID; HYPERFORIN; IONOPHORE; MESSENGER RNA; NORADRENALIN; PREGNANE X RECEPTOR; PROTONOPHORE; SEROTONIN; TETRAHYDROHYPERFORIN; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UNCLASSIFIED DRUG; CYTOCHROME P450 INDUCER; PHLOROGLUCINOL; TERPENE; TRANSIENT RECEPTOR POTENTIAL CHANNEL C; TRPC6 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANTIDEPRESSIVE ACTIVITY; AUTISM; BRAIN ISCHEMIA; CHANNEL GATING; COGNITION; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; EPILEPSY; HIPPOCAMPAL CA1 REGION; HIPPOCAMPAL CA3 REGION; HUMAN; IC50; MOLECULAR DYNAMICS; NEURONAL EFFECT; NONHUMAN; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTON TRANSPORT; PROTONOPHORIC ACTIVITY; STRUCTURE ACTIVITY RELATION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG EFFECTS; PHYSIOLOGY;

ANIMALS; CYTOCHROME P-450 ENZYME INDUCERS; DRUG STABILITY; HUMANS; PHLOROGLUCINOL; TERPENES; TRPC CATION CHANNELS;

EID: 84948753627     PISSN: 03034240     EISSN: 16175786     Source Type: Book Series    
DOI: 10.1007/112_2015_25     Document Type: Chapter

References (137)

1. Abbott AC, Calderon Toledo C, Aranguiz FC, Inestrosa NC, Varela-Nallar L (2013) Tetrahydro-hyperforin increases adult hippocampal neurogenesis in wild-type and APPswe/PS1ΔE9 mice. J Alzheimers Dis 34:873-885
2. Amaral MD, Pozzo-Miller L (2007) TRPC3 channels are necessary for brain-derived neurotrophic factor to activate a nonselective cationic current and to induce dendritic spine formation. J Neurosci 27:5179-5189
3. Barliya T, Mandel M, Livnat T, Weinberger D, Lavie G (2011) Degradation of HIF-1alpha under hypoxia combined with induction of Hsp90 polyubiquitination in cancer cells by hypericin: a unique cancer therapy. PLoS One 6:e22849
4. Bauer S, Stormer E, Johne A, Kruger H, Budde K, Neumayer HH et al (2003) Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John’s wort in renal transplant patients. Br J Clin Pharmacol 55:203-211
5. Biber A, Fischer H, Romer A, Chatterjee SS (1998) Oral bioavailability of hyperforin from Hypericum extracts in rats and human volunteers. Pharmacopsychiatry 31(Suppl 1):36-43
6. Bladt S, Wagner H (1994) Inhibition of MAO by fractions and constituents of Hypericum extract. J Geriatr Psychiatry Neurol 7(Suppl 1):S57-S59
7. Boiy A, Roelandts R, van den Oord J, de Witte PAM (2008) Photosensitizing activity of hypericin and hypericin acetate after topical application on normal mouse skin. Br J Dermatol 158:360-369
8. Bouron A, Oberwinkler J (2014) Contribution of calcium-conducting channels to the transport of zinc ions. Pflugers Arch 466:381-387
9. Breidenbach T, Hoffmann MW, Becker T, Schlitt H, Klempnauer J (2000a) Drug interaction of St John’s wort with cyclosporin. Lancet 355:1912
10. Breidenbach T, Kliem V, Burg M, Radermacher J, Hoffmann MW, Klempnauer J (2000b) Profound drop of cyclosporin A whole blood trough levels caused by St. John’s wort (Hypericum perforatum). Transplantation 69:2229-2230
11. Brenn A, Grube M, Jedlitschky G, Fischer A, Strohmeier B, Eiden M et al (2014) St. John’s Wort reduces beta-amyloid accumulation in a double transgenic Alzheimer’s disease mouse model-role of P-glycoprotein. Brain Pathol 24:18-24
12. Brockmoller J, Reum T, Bauer S, Kerb R, Hubner WD, Roots I (1997) Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 30(Suppl 2):94-101
13. Buchholzer ML, Dvorak C, Chatterjee SS, Klein J (2002) Dual modulation of striatal acetylcholine release by hyperforin, a constituent of St. John’s wort. J Pharmacol Exp Ther 301:714-719
14. Butterweck V, Schmidt M (2007) St. John’s wort: role of active compounds for its mechanism of action and efficacy. Wien Med Wochenschr 157:356-361
15. Butterweck V, Bockers T, Korte B, Wittkowski W, Winterhoff H (2002) Long-term effects of St. John’s wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. Brain Res 930:21-29
16. Caccia S, Gobbi M (2009) St. John’s wort components and the brain: uptake, concentrations reached and the mechanisms underlying pharmacological effects. Curr Drug Metab 10:1055-1065
17. Cantoni L, Rozio M, Mangolini A, Hauri L, Caccia S (2003) Hyperforin contributes to the hepatic CYP3A-inducing effect of Hypericum perforatum extract in the mouse. Toxicol Sci 75:25-30
18. Carvajal FJ, Inestrosa NC (2011) Interactions of AChE with Aβ aggregates in Alzheimer’s brain: therapeutic relevance of IDN 5706. Front Mol Neurosci 4:19
19. Carvajal FJ, Zolezzi JM, Tapia-Rojas C, Godoy JA, Inestrosa NC (2013) Tetrahydrohyperforin decreases cholinergic markers associated with amyloid-β plaques, 4-hydroxynonenal formation, and caspase-3 activation in AβPP/PS1 mice. J Alzheimers Dis 36:99-118
20. Cerpa W, Hancke JL, Morazzoni P, Bombardelli E, Riva A, Marin PP et al (2010) The hyperforin derivative IDN5706 occludes spatial memory impairments and neuropathological changes in a double transgenic Alzheimer’s mouse model. Curr Alzheimer Res 7:126-133
21. Chatterjee SS, Noldner M, Koch E, Erdelmeier C (1998) Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility. Pharmacopsychiatry 31(Suppl 1):7-15
22. Chatterjee S, Filippov V, Lishko P, Maximyuk O, Noldner M, Krishtal O (1999) Hyperforin attenuates various ionic conductance mechanisms in the isolated hippocampal neurons of rat. Life Sci 65:2395-2405
23. Chatterjee SS, Biber A, Weibezahn C (2001) Stimulation of glutamate, aspartate and gamma-aminobutyric acid release from synaptosomes by hyperforin. Pharmacopsychiatry 34(Suppl 1): S11-S19
24. Chen W, Oberwinkler H, Werner F, Gaßner B, Nakagawa H, Feil R et al (2013) Atrial natriuretic peptide-mediated inhibition of microcirculatory endothelial Ca2+ and permeability response to histamine involves cGMP-dependent protein kinase I and TRPC6 channels. Arterioscler Thromb Vasc Biol 33:2121-2129
25. Chung YH, Sun Ahn H, Kim D, Hoon Shin D, Su Kim S, Yong Kim K et al (2006) Immunohis-tochemical study on the distribution of TRPC channels in the rat hippocampus. Brain Res 1085:132-137
26. Clapham DE, Runnels LW, Strubing C (2001) The TRP ion channel family. Nat Rev Neurosci 2:387-396
27. Coskun PE, Beal MF, Wallace DC (2004) Alzheimer’s brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci USA101:10726-10731
28. Cott JM (1997) In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 30(Suppl 2):108-112
29. Davids LM, Kleemann B, Kacerovská D, Pizinger K, Kidson SH (2008) Hypericin phototoxicity induces different modes of cell death in melanoma and human skin cells. J Photochem Photobiol B 91:67-76
30. Dinamarca MC, Cerpa W, Garrido J, Hancke JL, Inestrosa NC (2006) Hyperforin prevents beta-amyloid neurotoxicity and spatial memory impairments by disaggregation of Alzheimer’s amyloid-beta-deposits. Mol Psychiatry 11:1032-1048
31. Ding Y, Winters A, Ding M, Graham S, Akopova I, Muallem S et al (2011) Reactive oxygen species-mediated TRPC6 protein activation in vascular myocytes, a mechanism for vasoconstrictor-regulated vascular tone. J Biol Chem 286:31799-31809
32. Dror N, Mandel M, Lavie G (2013) Unique anti-glioblastoma activities of hypericin are at the crossroad of biochemical and epigenetic events and culminate in tumor cell differentiation. PLoS One 8:e73625
33. Du W, Huang J, Yao H, Zhou K, Duan B, Wang Y (2010) Inhibition of TRPC6 degradation suppresses ischemic brain damage in rats. J Clin Invest 120:3480-3492
34. Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338:68-72
35. Duman CH, Duman RS (2015) Spine synapse remodeling in the pathophysiology and treatment of depression. Neurosci Lett 601:20-29
36. Duric V, Duman RS (2013) Depression and treatment response: dynamic interplay of signaling pathways and altered neural processes. Cell Mol Life Sci 70:39-53
37. Ernst E (1999) Second thoughts about safety of St John’s wort. Lancet 354:2014-2016
38. Faber ESL, Sedlak P, Vidovic M, Sah P (2006) Synaptic activation of transient receptor potential channels by metabotropic glutamate receptors in the lateral amygdala. Neuroscience 137:781-794
39. Fisunov A, Lozovaya N, Tsintsadze T, Chatterjee SS, Noldner M, Krishtal O (2000) Hyperforin modulates gating of P-type Ca2+ current in cerebellar Purkinje neurons. Pflugers Arch 440:427-434
40. Flockerzi V (2007) An introduction on TRP channels. Handb Exp Pharmacol (179):19
41. Fortin DA, Srivastava T, Dwarakanath D, Pierre P, Nygaard S, Derkach VA et al (2012) Brain-derived neurotrophic factor activation of CaM-kinase kinase via transient receptor potential canonical channels induces the translation and synaptic incorporation of GluA1-containing calcium-permeable AMPA receptors. J Neurosci 32:8127-8137
42. Froestl B, Steiner B, Muller WE (2003) Enhancement of proteolytic processing of the beta-amyloid precursor protein by hyperforin. Biochem Pharmacol 66:2177-2184
43. Fusco FR, Martorana A, Giampa C, De March Z, Vacca F, Tozzi A et al (2004) Cellular localization of TRPC3 channel in rat brain: preferential distribution to oligodendrocytes. Neurosci Lett 365:137-142
44. Gartner M, Muller T, Simon JC, Giannis A, Sleeman JP (2005) Aristoforin, a novel stable derivative of hyperforin, is a potent anticancer agent. Chembiochem 6:171-177
45. Gastpar M (2013) Hypericum extract WS ® 5570 for depression--an overview. Int J Psychiatry Clin Pract 17(Suppl 1):1-7
46. Gastpar M, Singer A, Zeller K (2006) Comparative efficacy and safety of a once-daily dosage of Hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 39:66-75
47. Gibon J, Tu P, Bouron A (2010) Store-depletion and hyperforin activate distinct types of Ca2+-conducting channels in cortical neurons. Cell Calcium 47:538-543
48. Gibon J, Richaud P, Bouron A (2011a) Hyperforin changes the zinc-storage capacities of brain cells. Neuropharmacology 61:1321-1326
49. Gibon J, Tu P, Bohic S, Richaud P, Arnaud J, Zhu M et al (2011b) The over-expression of TRPC6 channels in HEK-293 cells favours the intracellular accumulation of zinc. Biochim Biophys Acta Biomembr 1808:2807-2818
50. Gibon J, Deloulme JC, Chevallier T, Ladevèze E, Abrous DN, Bouron A (2012) The antidepres-sant hyperforin increases the phosphorylation of CREB and the expression of TrkB in a tissue-specific manner. Int J Neuropsychopharmacol 16(1):189-198
51. Griesi-Oliveira K, Acab A, Gupta AR, Sunaga DY, Chailangkarn T, Nicol X et al (2014) Modeling non-syndromic autism and the impact of TRPC6 disruption in human neurons. Mol Psychiatry. doi:10.1038/mp.2014.141
52. Griffith TN, Varela-Nallar L, Dinamarca MC, Inestrosa NC (2010) Neurobiological effects of Hyperforin and its potential in Alzheimer’s disease therapy. Curr Med Chem 17:391-406
53. Harteneck C, Gollasch M (2011) Pharmacological modulation of diacylglycerol-sensitive TRPC3/6/7 channels. Curr Pharm Biotechnol 12:35-41
54. Harteneck C, Leuner K (2014) TRP channels in neuronal and glial signal transduction. In: Heinbockel T (ed) Neurochemistry. InTech, Rijeka. doi:10.5772/58232. ISBN: 978-953-51-1237-2
55. Harteneck C, Plant TD, Schultz G (2000) From worm to man: three subfamilies of TRP channels. Trends Neurosci 23:159-166
56. Harteneck C, Frenzel H, Kraft R (2007) N-(p-amylcinnamoyl)anthranilic acid (ACA): a phospholipase A(2) inhibitor and TRP channel blocker. Cardiovasc Drug Rev 25:61-75
57. Heiser JH, Schuwald AM, Sillani G, Ye L, Muller WE, Leuner K (2013) TRPC6 channel-mediated neurite outgrowth in PC12 cells and hippocampal neurons involves activation of RAS/MEK/ ERK, PI3K, and CAMKIV signaling. J Neurochem 127:303-313
58. Hofmann T, Obukhov AG, Schaefer M, Harteneck C, Gudermann T, Schultz G (1999) Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature 397:259-263
59. Inestrosa NC, Tapia-Rojas C, Griffith TN, Carvajal FJ, Benito MJ, Rivera-Dictter A et al (2011) Tetrahydrohyperforin prevents cognitive deficit, Aβ deposition, tau phosphorylation and synaptotoxicity in the APPswe/PSEN1ΔE9 model of Alzheimer’s disease: a possible effect on APP processing. Transl Psychiatry 1:e20
60. Isacchi B, Bergonzi MC, Carnevali F, van der Esch SA, Vincieri FF, Bilia AR (2007) Analysis and stability of the constituents of St. John’s wort oils prepared with different methods. J Pharm Biomed Anal 45:756-761
61. Jensen AA, Fahlke C, Bjørn-Yoshimoto WE, Bunch L (2015) Excitatory amino acid transporters: recent insights into molecular mechanisms, novel modes of modulation and new therapeutic possibilities. Curr Opin Pharmacol 20:116-123
62. Kaehler ST, Sinner C, Chatterjee SS, Philippu A (1999) Hyperforin enhances the extracellular concentrations of catecholamines, serotonin and glutamate in the rat locus coeruleus. Neurosci Lett 262:199-202
63. Kandel BA, Ekins S, Leuner K, Thasler WE, Harteneck C, Zanger UM (2014) No activation of human pregnane X receptor by hyperforin-related phloroglucinols. J Pharmacol Exp Ther 348:393-400
64. Kasper S, Caraci F, Forti B, Drago F, Aguglia E (2010) Efficacy and tolerability of Hypericum extract for the treatment of mild to moderate depression. Eur Neuropsychopharmacol 20:747-765
65. Keller JH, Karas M, Muller WE, Volmer DA, Eckert GP, Tawab MA et al (2003) Determination of hyperforin in mouse brain by high-performance liquid chromatography/tandem mass spectrometry. Anal Chem 75:6084-6088
66. Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I (1996) Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 40:2087-2093
67. Kiewert C, Buchholzer ML, Hartmann J, Chatterjee SS, Klein J (2004) Stimulation of hippocampal acetylcholine release by hyperforin, a constituent of St. John’s wort. Neurosci Lett 364:195-198
68. Kim DS, Ryu HJ, Kim JE, Kang TC (2013) The reverse roles of transient receptor potential canonical channel-3 and 6 in neuronal death following pilocarpine-induced status epilepticus. Cell Mol Neurobiol 33:99-109
69. Krishtal O, Lozovaya N, Fisunov A, Tsintsadze T, Pankratov Y, Kopanitsa M et al (2001) Modulation of ion channels in rat neurons by the constituents of Hypericum perforatum. Pharmacopsychiatry 34(Suppl 1):S74-S82
70. Laakmann G, Schule C, Baghai T, Kieser M (1998) St. John’s wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31(Suppl 1):54-59
71. Lecrubier Y, Clerc G, Didi R, Kieser M (2002) Efficacy of St. John’s wort extract WS 5570 in major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 159:1361-1366
72. Lee JY, Duke RK, Tran VH, Hook JM, Duke CC (2006) Hyperforin and its analogues inhibit CYP3A4 enzyme activity. Phytochemistry 67:2550-2560
73. Lessard CB, Lussier MP, Cayouette S, Bourque G, Boulay G (2005) The overexpression of presenilin2 and Alzheimer’s-disease-linked presenilin2 variants influences TRPC6-enhanced Ca2+ entry into HEK293 cells. Cell Signal 17:437-445
74. Leuner K, Kazanski V, Muller M, Essin K, Henke B, Gollasch M et al (2007) Hyperforin-a key constituent of St. John’s wort specifically activates TRPC6 channels. FASEB J 21:4101-4111
75. Leuner K, Heiser JH, Derksen S, Mladenov MI, Fehske CJ, Schubert R et al (2010) Simple 2,4-diacylphloroglucinols as classic transient receptor potential-6 activators--identification of a novel pharmacophore. Mol Pharmacol 77:368-377
76. Leuner K, Li W, Amaral MD, Rudolph S, Calfa G, Schuwald AM et al (2013) Hyperforin modulates dendritic spine morphology in hippocampal pyramidal neurons by activating Ca2+-permeable TRPC6 channels. Hippocampus 23:40-52
77. Li Y, Jia YC, Cui K, Li N, Zheng ZY, Wang YZ et al (2005) Essential role of TRPC channels in the guidance of nerve growth cones by brain-derived neurotrophic factor. Nature 434:894-898
78. Li W, Calfa G, Larimore J, Pozzo-Miller L (2012) Activity-dependent BDNF release and TRPC signaling is impaired in hippocampal neurons of Mecp2 mutant mice. Proc Natl Acad Sci U S A 109:17087-17092
79. Lin Y (2013) Neuroprotectin D1 attenuates brain damage induced by transient middle cerebral artery occlusion in rats through TRPC6/CREB pathways. Mol Med Rep 8:543-550
80. Lin Y, Zhang JC, Fu J, Chen F, Wang J, Wu ZL et al (2013) Hyperforin attenuates brain damage induced by transient middle cerebral artery occlusion (MCAO) in rats via inhibition of TRPC6 channels degradation. J Cereb Blood Flow Metab 33:253-262
81. Lin L, Yee SW, Kim RB, Giacomini KM (2015) SLC transporters as therapeutic targets: emerging opportunities. Nat Rev Drug Discov. doi:10.1038/nrd4626
82. Linde K, Berner MM, Kriston L (2008) St John’s wort for major depression. Cochrane Database Syst Rev CD000448
83. Mai I, Störmer E, Bauer S, Kruger H, Budde K, Roots I (2003) Impact of St John’s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 18:819-822
84. Maisenbacher P, Kovar KA (1992) Analysis and stability of Hyperici oleum. Planta Med 58:351-354
85. Marsh WL, Davies JA (2002) The involvement of sodium and calcium ions in the release of amino acid neurotransmitters from mouse cortical slices elicited by hyperforin. Life Sci 71:2645-2655
86. McGurk JS, Shim S, Kim JY, Wen Z, Song H, Ming GL (2011) Postsynaptic TRPC1 function contributes to BDNF-induced synaptic potentiation at the developing neuromuscular junction. J Neurosci 31:14754-14762
87. McKinnon MC, Yucel K, Nazarov A, MacQueen GM (2009) A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. J Psychiatry Neurosci 34:41-54
88. Montecinos-Oliva C, Schuller A, Parodi J, Melo F, Inestrosa NC (2014) Effects of tetrahydrohy-perforin in mouse hippocampal slices: neuroprotection, long-term potentiation and TRPC channels. Curr Med Chem 21:3494-3506
89. Montecinos-Oliva C, Schuller A, Inestrosa NC (2015) Tetrahydrohyperforin: a neuroprotective modified natural compound against Alzheimer’s disease. Neural Regen Res 10:552-554
90. Montell C, Birnbaumer L, Flockerzi V (2002) The TRP channels, a remarkably functional family. Cell 108:595-598
91. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM et al (2000) St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 97:7500-7502
92. Müller WE (2003) Current St. John’s wort research from mode of action to clinical efficacy. Pharmacol Res 47:101-109
93. Müller M, Essin K, Hill K, Beschmann H, Rubant S, Schempp CM et al (2008) Specific TRPC6 channel activation, a novel approach to stimulate keratinocyte differentiation. J Biol Chem 283:33942-33954
94. Muñoz RF, Cuijpers P, Smit F, Barrera AZ, Leykin Y (2010) Prevention of major depression. Annu Rev Clin Psychol 6:181-212
95. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C et al (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2197-2223
96. Nilius B (2012) Transient receptor potential (TRP) channels in the brain: the good and the ugly. Eur Rev 20:343-355
97. Nilius B, Szallasi A (2014) Transient receptor potential channels as drug targets: from the science of basic research to the art of medicine. Pharmacol Rev 66:676-814
98. Nilius B, Szallasi A (2015) Are brain TRPs viable targets for curing neurodegenerative disorders and improving mental health? In: Szallasi A (ed) TRP channels as therapeutic targets. From basic science to clinical use. Academic, San Diego, pp 419-456
99. Nöldner M, Schötz K (2002) Rutin is essential for the antidepressant activity of Hypericum perforatum extracts in the forced swimming test. Planta Med 68:577-580
100. Novelli M, Beffy P, Menegazzi M, De Tata V, Martino L, Sgarbossa A et al (2014) St. John’s wort extract and hyperforin protect rat and human pancreatic islets against cytokine toxicity. Acta Diabetol 51:113-121
101. Obach RS (2000) Inhibition of human cytochrome P450 enzymes by constituents of St. John’s wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 294:88-95
102. Paulke A, Nöldner M, Schubert-Zsilavecz M, Wurglics M (2008) St. John’s wort flavonoids and their metabolites show antidepressant activity and accumulate in brain after multiple oral doses. Pharmazie 63:296-302
103. Penninx BWJH, Milaneschi Y, Lamers F, Vogelzangs N (2013) Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med 11:129
104. Philippu A (2001) In vivo neurotransmitter release in the locus coeruleus-effects of hyperforin, inescapable shock and fear. Pharmacopsychiatry 34(Suppl 1):S111-S115
105. Rothley M, Schmid A, Thiele W, Schacht V, Plaumann D, Gartner M et al (2009) Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo. Int J Cancer 125:34-42
106. Roz N, Rehavi M (2003) Hyperforin inhibits vesicular uptake of monoamines by dissipating pH gradient across synaptic vesicle membrane. Life Sci 73:461-470
107. Roz N, Rehavi M (2004) Hyperforin depletes synaptic vesicles content and induces compartmental redistribution of nerve ending monoamines. Life Sci 75:2841-2850
108. Roz N, Mazur Y, Hirshfeld A, Rehavi M (2002) Inhibition of vesicular uptake of monoamines by hyperforin. Life Sci 71:2227-2237
109. Samapati R, Yang Y, Yin J, Stoerger C, Arenz C, Dietrich A et al (2012) Lung endothelial Ca2+and permeability response to platelet-activating factor is mediated by acid sphingomyelinase and transient receptor potential classical 6. Am J Respir Crit Care Med 185:160-170
110. Scimemi A (2014) Structure, function, and plasticity of GABA transporters. Front Cell Neurosci 8:161
111. Sell TS, Belkacemi T, Flockerzi V, Beck A (2014) Protonophore properties of hyperforin are essential for its pharmacological activity. Sci Rep 4:7500
112. šemeláková M, Mikeš J, Jendželovsky´ R, Fedoročko P (2012) The pro-apoptotic and anti-invasive effects of hypericin-mediated photodynamic therapy are enhanced by hyperforin or aristoforin in HT-29 colon adenocarcinoma cells. J Photochem Photobiol B 117:115-125
113. Singer A, Wonnemann M, Müller WE (1999) Hyperforin, a major antidepressant constituent of St. John’s Wort, inhibits serotonin uptake by elevating free intracellular Na+. J Pharmacol Exp Ther 290:1363-1368
114. Singer A, Schmidt M, Hauke W, Stade K (2011) Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial. Phytomedicine 18:739-742
115. Sossin WS, Barker PA (2007) Something old, something new: BDNF-induced neuron survival requires TRPC channel function. Nat Neurosci 10:537-538
116. Staffeldt B, Kerb R, Brockmoller J, Ploch M, Roots I (1994) Pharmacokinetics of hypericin and pseudohypericin after oral intake of the Hypericum perforatum extract LI 160 in healthy volunteers. J Geriatr Psychiatry Neurol 7(Suppl 1):S47-S53
117. Strübing C, Krapivinsky G, Krapivinsky L, Clapham DE (2001) TRPC1 and TRPC5 form a novel cation channel in mammalian brain. Neuron 29:645-655
118. Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H (1984) Inhibition of monoamine oxidase by hypericin. Planta Med 50:272-274
119. Thiede HM, Walper A (1994) Inhibition of MAO and COMT by Hypericum extracts and hypericin. J Geriatr Psychiatry Neurol 7(Suppl 1):S54-S56
120. Travis S, Coupland NJ, Silversone PH, Huang Y, Fujiwara E, Carter R et al (2014) Dentate gyrus volume and memory performance in major depressive disorder. J Affect Disord 172C:159-164
121. Treiber K, Singer A, Henke B, Müller WE (2005) Hyperforin activates nonselective cation channels (NSCCs). Br J Pharmacol 145:75-83
122. Tu P, Kunert-Keil C, Lucke S, Brinkmeier H, Bouron A (2009) Diacylglycerol analogues activate second messenger-operated calcium channels exhibiting TRPC-like properties in cortical neurons. J Neurochem 108:126-138
123. Tu P, Gibon J, Bouron A (2010) The TRPC6 channel activator hyperforin induces the release of zinc and calcium from mitochondria. J Neurochem 112:204-213
124. Vance KM, Ribnicky DM, Hermann GE, Rogers RC (2014) St. John’s Wort enhances the synaptic activity of the nucleus of the solitary tract. Nutrition 30:S37-S42
125. Vennekens R, Menigoz A, Nilius B (2012) TRPs in the brain. Rev Physiol Biochem Pharmacol 163:27-64
126. Verotta L, Appendino G, Belloro E, Jakupovic J, Bombardelli E (1999) Furohyperforin, a prenylated phloroglucinol from St. John’s wort (Hypericum perforatum). J Nat Prod 62:770-772
127. Verotta L, Lovaglio E, Sterner O, Appendino G, Bombardelli E (2004) Modulation of chemoselectivity by protein additives. Remarkable effects in the oxidation of hyperforin. J Org Chem 69:7869-7874
128. Von Bohlen Und Halbach O, Hinz U, Unsicker K, Egorov AV (2005) Distribution of TRPC1 and TRPC5 in medial temporal lobe structures of mice. Cell Tissue Res 322:201-206
129. Watkins RE, Maglich JM, Moore LB, Wisely GB, Noble SM, Davis-Searles PR et al (2003) 1 Å crystal structure of human PXR in complex with the St. John’s wort. Biochemistry 42:1430-1438
130. Wentworth JM, Agostini M, Love J, Schwabe JW, Chatterjee VK (2000) St John’s wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 166:R11-R16
131. Whitten DL, Myers SP, Hawrelak JA, Wohlmuth H (2006) The effect of St John’s wort extracts on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol 62:512-526
132. Wolfender JL, Verotta L, Belvisi L, Fuzzati N, Hostettmann K (2003) Structural investigations isomeric oxidised forms of hyperforin by HPLC-NMR and HPLC-MSn. Phytochem Anal 14:290-297
133. Wonnemann M, Singer A, Muller WE (2000) Inhibition of synaptosomal uptake of 3H-L-glutamate and 3H-GABA by hyperforin, a major constituent of St. John’s wort: the role of amiloride sensitive sodium conductive pathways. Neuropsychopharmacology 23:188-197
134. Wu LJ, Sweet TB, Clapham DE (2010) International union of basic and clinical pharmacology. LXXVI. Current progress in the mammalian TRP ion channel family. Pharmacol Rev 62:381-404
135. Yoshitake T, Iizuka R, Yoshitake S, Weikop P, Müller WE, Ogren SO et al (2004) Hypericum perforatum L (St. John’s wort) preferentially increases extracellular dopamine levels in the rat prefrontal cortex. Br J Pharmacol 142:414-418
136. Zanoli P, Rivasi M, Baraldi C, Baraldi M (2002) Pharmacological activity of hyperforin acetate in rats. Behav Pharmacol 13:645-651
137. Zhou S, Lim LY, Chowbay B (2004) Herbal modulation of P-glycoprotein. Drug Metab Rev 36:57-104